Skip to Main Content
Table 1.

Effect of docetaxel on splenic cell populations

CellsTreatmentPretreatmentTime posttreatment
Day 1Day 2Day 3Day 4Day 7
Splenocytes PBS 1.1 × 108  1.4 × 108  1.1 × 108  1.1 × 108  9.6 × 107  1.1 × 108  
 Docetaxel —  8.1 × 107  7.4 × 107  8.6 × 107  1.1 × 108  1.1 × 108  
CD4+ PBS 18% 2.0 × 107 17% 2.4 × 107 18% 2.0 × 107 17% 1.9 × 107 15% 1.4 × 107 25% 2.8 × 107 
 Docetaxel —  19% 1.5 × 107 19% 1.4 × 107 19% 1.6 × 107 10% 1.1 × 107 19% 2.1 × 107 
CD8+ PBS 13% 1.4 × 107 11% 1.5 × 107 8% 8.8 × 106 10% 1.1 × 106 9% 8.6 × 106 14% 1.5 × 107 
 Docetaxel —  13% 1.0 × 107 14% 1.0 × 107 12% 1.0 × 107 7% 7.7 × 106 13% 1.4 × 107 
CD19+ PBS 60% 6.6 × 107 62% 8.7 × 107 64% 7.0 × 107 58% 6.4 × 107 52% 5.0 × 107 61% 6.7 × 107 
 Docetaxel —  54% 4.4 × 107 58% 4.3 × 107 52% 4.5 × 107 40% 4.4 × 107 49% 5.4 × 107 
DX5+ PBS 2.8% 3.1 × 106 2.7% 3.7 × 106 2.4% 2.6 × 106 2.5% 2.8 × 106 2.0% 1.9 × 106 3.4% 3.7 × 106 
 Docetaxel —  2.7% 2.2 × 106 2.5% 1.8 × 106 2.2% 1.9 × 106 1.8% 2.0 × 106 4.4% 4.8 × 106 
Tregs PBS 5% 5.5 × 106 4.0% 5.6 × 106 8.8% 9.7 × 106 7.2% 7.9 × 106 8.1% 7.8 × 106 7.3% 8.0 × 106 
 Docetaxel —  6.7% 5.4 × 106 11.5% 8.5 × 106 9.5% 8.2 × 106 9.2% 1.0 × 107 8.5% 9.4 × 106 
CellsTreatmentPretreatmentTime posttreatment
Day 1Day 2Day 3Day 4Day 7
Splenocytes PBS 1.1 × 108  1.4 × 108  1.1 × 108  1.1 × 108  9.6 × 107  1.1 × 108  
 Docetaxel —  8.1 × 107  7.4 × 107  8.6 × 107  1.1 × 108  1.1 × 108  
CD4+ PBS 18% 2.0 × 107 17% 2.4 × 107 18% 2.0 × 107 17% 1.9 × 107 15% 1.4 × 107 25% 2.8 × 107 
 Docetaxel —  19% 1.5 × 107 19% 1.4 × 107 19% 1.6 × 107 10% 1.1 × 107 19% 2.1 × 107 
CD8+ PBS 13% 1.4 × 107 11% 1.5 × 107 8% 8.8 × 106 10% 1.1 × 106 9% 8.6 × 106 14% 1.5 × 107 
 Docetaxel —  13% 1.0 × 107 14% 1.0 × 107 12% 1.0 × 107 7% 7.7 × 106 13% 1.4 × 107 
CD19+ PBS 60% 6.6 × 107 62% 8.7 × 107 64% 7.0 × 107 58% 6.4 × 107 52% 5.0 × 107 61% 6.7 × 107 
 Docetaxel —  54% 4.4 × 107 58% 4.3 × 107 52% 4.5 × 107 40% 4.4 × 107 49% 5.4 × 107 
DX5+ PBS 2.8% 3.1 × 106 2.7% 3.7 × 106 2.4% 2.6 × 106 2.5% 2.8 × 106 2.0% 1.9 × 106 3.4% 3.7 × 106 
 Docetaxel —  2.7% 2.2 × 106 2.5% 1.8 × 106 2.2% 1.9 × 106 1.8% 2.0 × 106 4.4% 4.8 × 106 
Tregs PBS 5% 5.5 × 106 4.0% 5.6 × 106 8.8% 9.7 × 106 7.2% 7.9 × 106 8.1% 7.8 × 106 7.3% 8.0 × 106 
 Docetaxel —  6.7% 5.4 × 106 11.5% 8.5 × 106 9.5% 8.2 × 106 9.2% 1.0 × 107 8.5% 9.4 × 106 

NOTE: C57BL/6 mice (n = 5 per group) were given 0.5 mg docetaxel i.p. on days −4, −2, and 0. Control mice received PBS only. Mice were sacrificed 1, 2, 3, 4, and 7 d posttreatment. After lysis of RBC, splenocytes were counted and stained for T cells (CD3+, CD4+, CD8+), B cells (CD19+), natural killer cells (DX5+), and Tregs (CD4+CD25+FoxP3+). Of the CD4+cells that expressed CD25, >98% also stained positive for FoxP3. Cells were analyzed by flow cytometry. Percentages denote the percent of splenocytes. Bold numbers indicate a significant difference (P < 0.05) in docetaxel versus PBS treated mice. This experiment was repeated twice.

Close Modal

or Create an Account

Close Modal
Close Modal